Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Soligenix shares spike after T-cell lymphoma candidate HyBryte aces compatibility study

Published 2023-05-04, 11:00 a/m
© Reuters.  Soligenix shares spike after T-cell lymphoma candidate HyBryte aces compatibility study
IXIC
-
SNGX
-

Proactive Investors - Soligenix shares more than doubled on Thursday after the biopharmaceutical company announced positive results from a compatibility study of its investigational therapeutic HyBryte in cutaneous T-cell lymphoma (CTCL) using the commercially ready Daavlin Series 7 visible light device.

The company is developing and moving toward the potential commercialization of HyBryte (synthetic hypericin sodium) for the treatment of CTCL, a class of non-Hodgkin’s lymphoma.

The study, led by principal investigator Dr Brian Poligone at the Rochester Skin Lymphoma Medical Group, enrolled nine patients to receive eight weeks of HyBryte treatment of their cancerous lesions, with the response assessed after 10 weeks using the Composite Assessment of Index Lesion Severity (CAILS) score.

The company said the study achieved its purpose of establishing that any light device capable of producing visible light of an appropriate and consistent wavelength of 500 to 650 nm is suitable for use with HyBryte and extends the pharmacokinetic profile using a recently developed, more sensitive hypericin assay.

Soligenix (NASDAQ:SNGX) added that the study outcomes also confirmed the results of the recently published Phase 3 FLASH trial for CTCL patients which found 16% of the participants receiving HyBryte achieved at least a 50% reduction in their lesions compared to 4% of patients in the placebo group at eight weeks.

“Important corporate objectives for the study were to replicate results previously observed in the FLASH study, while using finished drug product manufactured by our proposed commercial contract manufacturer and activated using a commercially viable light device," said Soligenix CEO Dr Christopher J Schaber in a statement.

"We look forward to continuing to work with Dr Poligone and all of our committed clinical investigators to make HyBryte available to this underserved orphan patient population."

Soligenix shares were up 138.7% at US$3.39 on Thursday morning.

Read more on Proactive Investors CA

Disclaimer

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.